Cryoport, Inc. (CYRX) Stock

Cryoport, Inc. (CYRX) is a Healthcare stock trading at $15.02 (as of 2026-06-18), with a market capitalization of $790.81M and a trailing P/E of 10.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee.

Valuation — source: SEC EDGAR (first-party)
Price$15.02
Market Cap$790.81M
P/E Ratio10.2
EV / EBITDA-44.3
Price / Book1.49
Price / Sales4.03
DCF Value (model)$-3.52
DCF Upside vs Price-123.4%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$176.18M
Net Margin44.4%
Return on Equity16.1%
Current Ratio2.09
Revenue Growth (YoY)16.5%
EPS Growth (YoY)-10.7%
FCF Growth (YoY)-16.8%
Financial Health — source: SEC EDGAR
Altman Z-Score0.93 (distress)
Valuation vs Sector & Industry
Stock P/E10.2
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-51.1%
vs Industry-39.9%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderCADIAN CAPITAL MANAGEMENT, LP ($39.55M)
Institutional Holders Tracked10
Congressional Trades (recent)6
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOJerrell W. Shelton
Employees1,090
CountryUS
IPO Date2005-08-22

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • LENZ Therapeutics, Inc. (LENZ)
  • BioAge Labs, Inc. (BIOA)
  • Ginkgo Bioworks Holdings, Inc. (DNA)
  • Maravai LifeSciences Holdings, Inc. (MRVI)
  • Sinovac Biotech Ltd. (SVA)
  • Eton Pharmaceuticals, Inc. (ETON)
  • PepGen Inc. (PEPG)
  • Solid Biosciences Inc. (SLDB)
CYRX earnings history · CYRX institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.